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D6-04 Molecular Biology & Prognostic Factors, Thu, 12:30 - 14:15
Increased numbers of endothelial progenitor cells in peripheral 
blood and tumour specimens in non small cell lung cancer patients. 
A methodological challenge and ongoing debate on the clinical 
relevance
Pircher, Andreas Skvortsov, Sergej Dlaska, Margit Untergasser, G 
Kaehler, Christian M. Schmid, Thomas Hilbe, Wolfgang 
Medical University Innsbruck, Innsbruck, Austria
Background: Preclinical studies demonstrated that bone marrow 
derived endothelial progenitor cells (EPC) play an important role in 
neovascularisation and tumour growth. However, the clinical relevance 
of EPC on blood vessel formation in NSCLC is unclear. EPC represent 
an immature subset of CD34 positive cells expressing the glykosylated 
polypeptide CD133. Early EPC, which are found in the bone marrow, 
are characterised by their expression of CD34, CD133 and VEGFR2 
(KDR). More mature EPC are found in peripheral blood and are posi-
tive for VEGFR2 and CD34, but have lost CD133. EPC numbers in 
the circulation are very low and therefore their detection is technically 
challenging. In the present study two different immuncytological tech-
niques are presented and compared with each other. In addition, EPC 
numbers were correlated with plasma levels of VEGF, which is known 
to be the major trigger to mobilize EPC. Furthermore, the distribution 
and frequency of CD133 positive EPC in fresh frozen tumour speci-
mens were deﬁned.
Method: 10 NSCLC patients and 5 control patients were analysed in 
the present study. Blood analyses were done before and after surgery. 
EPC were isolated from whole blood by using magnetic beads coupled 
to an antibody directed against CD34 (MACS). After the positive selec-
tion, CD34 MNC were divided into two groups. One group underwent 
FACS analyses labelled with CD34, CD133, VEGFR2, CD45 and 
VE-Cadherin. The other group was assessed by immunocytological 
staining for CD133 (MZA). Cryostat sections were stained for CD133, 
CD31 and Cytokeratin A7. Serum levels of VEGF were quantiﬁed by 
sandwich ELISA.
Results: Compared to the control group, in NSCLC patients, EPC 
counts were signiﬁcantly elevated in peripheral blood before and after 
surgery. The presented alternative method, the MZA assay, correlated 
statistically signiﬁcantly with the standard method, the FACS analysis 
for CD34 VEGFR2 double positive cells. The major advantage of MZA 
was that even singular positive cells were detectable. Taken pre- and 
post-surgery measurements together, a statistically relevant/signiﬁcant 
trend between EPC numbers and VEGF levels was detected. In seven 
of ten tumour samples, increased numbers of CD133 positive cells 
were found and in some cases capillary forming CD133 positive struc-
tures were detectable. All EPC counts measured in the tumour patients 
were statistically signiﬁcantly elevated compared with the healthy 
control group.
Conclusions: A signiﬁcant increase of EPC was detected in patients 
with NSCLC, suggesting an involvement of EPC in tumour vasculo-
genesis and tumour growth in these patients. The MZA method is a 
valuable alternative for the detection of EPC compared to the FACS 
analysis in the peripheral blood, due to its ability to measure even 
singular positive cells. 
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Genomic profile of invasion in lung adenocarcinoma with 
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Background: Bronchioloalveolar carcinoma (BAC) is a subtype 
of lung adenocarcinoma (ADC) that by deﬁnition lacks evidence of 
stromal, vascular or pleural invasion. However, the histological criteria 
for diagnosis, their interpretation and the pre-invasive concept of BAC 
remain controversial. We used array comparative genomic hybridiza-
tion (CGH) to compare the genome-wide changes of BAC between no 
or possible micro-invasive samples with invasive AWBF samples to 
identify candidate genetic markers for invasion or poor prognosis. 
Methods: Genomic proﬁles of 14 non- or micro-invasive BAC and 15 
invasive AWBF were obtained using the whole genome submegabase 
resolution tiling set (SMRT) CGH arrays. Candidate marker genes for 
invasion were selected using multiple computational tools. Findings 
were validated in silico, by ﬂuorescent in situ hybridization (FISH) and 
by quantitative polymerase chain reaction (qPCR) using independent 
lung adenocarcinoma samples.
Results: Genomic proﬁles of non- and micro-invasive BAC cannot be 
distinguished, both showing mainly low copy gains on 1p, 2q, 5p, 7p, 
11p, 11q, 12q, 16p, 16q, 17q, 20q and 21q. Most aberrations occurred 
at the sub-telomeric chromosomal regions. AWBF had a similar pattern 
of chromosomal aberrations but with greater variability, frequency and 
range. In addition, deletions were more evident mainly on 3p, 4q, 5q, 
6q and 13q. Synchronous BAC and invasive AWBF from the same 
patient showed increased genomic instability in the latter. Progression 
was also noted between the BAC-like and invasive areas of AWBF. We 
identiﬁed 113 candidate marker genes for tumor invasion and pro-
gression and validated in silico one quarter of them as poor prognotic 
markers in early stage ADC. We further validated the ampliﬁcation 
and overexpression of two genes, PDCD6 and TERT, both located on 
chromosome 5p that showed prominent genomic change. PDCD6 is a 
novel poor prognostic marker for overall survival (HR=4.94, 95% CI 
1.22-8.52, p=0.02) in early stage ADC patients. 
Conclusions: Invasive AWBF can be molecularly distinguished from 
BAC by greater genomic aberrations, which may include markers for 
invasion and poor prognosis for early lung ADC. 
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Detection of circulating tumour cells from peripheral 
blood samples by a novel cell concentration method and 
immunohistochemistry (IHC) compared with reverse 
transcriptase-polymerase chain reaction (RT-PCR) in Stage III/IV 
Non-small cell lung cancer (NSCLC)
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Background: The prognosis of advanced NSCLC remains poor despite 
aggressive treatment such as concurrent chemoradiotherapy, which can 
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be associated with signiﬁcant morbidity. This may reﬂect our current 
limitations in staging lung cancer, particularly in detecting early or 
occult metastases. Several recent studies have demonstrated the ability 
to detect circulating lung tumour cells by RT-PCR using several gene 
products and the prognositc value of this investigation. There have been 
few studies exploring the use of IHC to detect circulating tumour cells. 
In these studies, IHC was found to be inferior to RT-PCR. The aim of 
this study was to assess the utility of a novel cell separation method 
called RosetteSep to generate a concentrated pellet of non-hemato-
logic cells from peripheral blood, which would allow for potentially 
improved detection of circulating tumour cells by cellular morphology 
and IHC stains for CEA, CK19, TTF1 and Moc1 compared with RT-
PCR using mRNA products of the same genes.
Methods: Forty Stage III or IV, previously untreated, NSCLC patients 
were accrued at consultation at the Vancouver Cancer Centre (VCC). 
Twenty healthy volunteer subjects with no known prior malignancy, 
lung disease or ongoing infection were recruited by letter and poster 
and accrued at VCC. Each consented subject had a total of 17 ml of 
peripheral blood drawn. The ﬁrst 2 ml were discarded to avoid epi-
thelial cell contamination from the needle prick through the skin and 
the remaining 15 ml were collected into heparin tubes. CD45 positive 
cells were depleted using samples incubated with RosetteSep CD45 
Depletion Cocktail (StemCell Technologies Inc) to create cell concen-
trate pellet samples. Half of this sample was used to create a cell block 
and slices were taken for celular morphology and IHC using stains 
for CEA, CK19, TTF1 and Moc1. The second half of this sample was 
analyzed using RT-PCR to detect the gene products of CEA, CK19, 
TTF1 and Moc1. 
Results: IHC was reported positive if there was at least 30% cyto-
plasmic staining for CEA, CK19 and Moc1 and at least 30% nuclear 
staining for TTF1. Cell morphology was used to conﬁrm the presence 
of malignant cells in the cell block specimen. The results of RT-PCR 
were reported as a relative quantity of gene expression in each sample. 
The detection rate of circulating tumour cells in NSCLC patients by 
RT-PCR was comparable to the detection rates demonstrated in previ-
ous studies. The detection rate of circulating tumour cells by IHC was 
lower than with RT-PCR but the difference was not signiﬁcant. No false 
positives were noted in the healthy volunteers. 
Conclusions: This novel cell concentration method improved IHC 
detection of circulating tumour cells from peripheral blood samples of 
NSCLC patients. Further reﬁnement of this technique may prove that 
a smaller volume of blood is required for IHC detection of circulating 
tumour cells, allowing for better clinical applicability of this investiga-
tion. This may ultimately improve “staging” of patients to improve 
selection of patients for appropriate therapies. Finally, the creation of 
a cell block would allow for tissue banking for future IHC studies in 
NSCLC.
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Background: Current staging methods are imprecise for predicting 
the outcome of treatment of NSCLC. The goal of this project was to 
develop a gene expression proﬁle for stage I and II NSCLC that is able 
to identify patients that have a high risk of disease progression within 
2-3 years after initial diagnosis. 
Methods: We used whole-genome gene expression microarrays to 
analyze frozen-tumor samples from 172 patients (pT1&2, N0&1, MO), 
who had undergone complete surgical resection in 5 European institu-
tions. Randomly generated numbers were used to assign 2/3 of the 
samples to an algorithm training group with the remaining 1/3 set aside 
for independent validation. Cox proportional hazards models were used 
to evaluate the association between the level of expression and patient 
survival. We used risk scores and nearest centroid analysis to develop a 
gene-expression model for the prediction of treatment outcome. 10-fold 
cross validation was used to prevent model over-training.
Results: 72 genes that correlated with survival were identiﬁed by 
analyzing microarray data and risk scores. Based on the expression of 
these genes, patients in training and validation groups were classiﬁed 
as either high or low risk. Analysis of predicted risk groups revealed 
signiﬁcantly different survival distributions for patients in both the 
training set (p<0.001) and independent validation set (p=0.01). Genes 
in our prognostic signature are enriched for genes associated with im-
mune response, antigen binding and protein modiﬁcation/ubiquination. 
Conclusions: Our 72-gene signature is closely associated with overall 
survival of completely-resected NSCLC patients. 
